Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 7/20 | 0.75 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | LIPE | Q05469 | 1/20 | 0.38 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2428670 | 0.90 | MGLL (0.62) | MGLLFFAR4GPR119LIPEABHD6 | |
| SCHEMBL2424111 | 0.88 | MGLL (0.59) | MGLLGPR119IDO1RORC | |
| SCHEMBL2427005 | 0.88 | MGLL (0.59) | MGLLGPR119IDO1RORC | |
| SCHEMBL2428771 | 0.88 | MGLL (0.59) | MGLLGPR119IDO1RORC | |
| SCHEMBL20399201 | 0.87 | MGLL (0.76) | MGLLFFAR4 | |
| SCHEMBL2427031 | 0.87 | MGLL (0.57) | MGLLIDO1RORC | |
| SCHEMBL20397181 | 0.86 | MGLL (1.00) | MGLLFFAR4ABHD6 | |
| SCHEMBL2424183 | 0.85 | MGLL (0.55) | MGLLGPR119IDO1 | |
| SCHEMBL2427027 | 0.85 | MGLL (0.55) | MGLLGPR119IDO1 | |
| SCHEMBL2423590 | 0.85 | MGLL (0.55) | MGLLGPR119IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3571202-B1 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | PFIZER (US) | 2021-06-30 | — | — | EP | disclosed |
| US-10858373-B2 | Heterocyclic spiro compounds as MAGL inhibitors | PFIZER INC. (US) | 2020-12-08 | — | — | US | disclosed |
| US-20190292203-A1 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | PFIZER INC. (US) | 2019-09-26 | — | — | US | disclosed |
| US-20180208608-A1 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | PFIZER (US) | 2018-07-26 | — | — | US | disclosed |
| EP-2367830-A1 | 1-OXA-8-AZASPIRO [4, 5] DECANE- 8 -CARBOXAMIDE COMPOUNDS AS FAAH INHIBITORS | Pfizer Inc. (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20110230493-A1 | 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors | PFIZER INC. | 2011-09-22 | — | — | US | disclosed |
| WO-2010058318-A1 | 1-OXA-8-AZASPIRO [4, 5 ] DECANE- 8 -CARBOXAMIDE COMPOUNDS AS FAAH INHIBITORS | PFIZER INC. (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292203-A1 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | MAG, MAGI3, APC | MGLL 16/4885FFAR4 3900/4885GPR119 1000/4885 |
| US-20180208608-A1 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | MAG, MAGI3, APC | MGLL 16/4885FFAR4 3900/4885GPR119 1000/4885 |
| US-20110230493-A1 | 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors | FAAH, FAAH2, FFAR1 | MGLL 246/4885FFAR4 15/4885GPR119 58/4885 |
| US-10858373-B2 | Heterocyclic spiro compounds as MAGL inhibitors | MAG, MAGI3, APC | MGLL 16/4885FFAR4 3900/4885GPR119 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.